27648073|t|Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding
27648073|a|Background. Heavy menstrual bleeding (HMB) is a common gynecological complaint affecting quality of life. Objectives. To assess knowledge on diagnosis and treatments of HMB of Latin American (LA) obstetricians and gynecologists (OBGYNs). Methods. A survey was conducted during a scientific meeting, organized to provide updated information on topics of reproductive medicine to OBGYNs from 12 LA countries who were invited to respond to a multiple-choice questionnaire. Results. Of the 210 OBGYNs participating in the survey, from 169 (80.4%) to 203 (96.7%) answered the questions. Most respondents (80%) gave accurate answers regarding the amount of blood loss which defines HMB, underreported the proportion of women who consulted due to HMB, and were aware that the use of combined oral contraceptives (COCs) with ethynyl estradiol is not an adequate treatment in women with HMB. Female OBGYNs and those who worked in the private sector were more prone to report a higher possibility of improvement of HMB with a COC that contained estradiol valerate and dienogest or with a levonorgestrel - releasing intrauterine system. Conclusions. In general, the respondents were aware of the importance of HMB in gynecological practice and of the new medical treatments and underreported the proportion of women who consulted due to HMB.
27648073	13	27	Latin American	T098	UMLS:C1553378
27648073	28	59	Obstetricians and Gynecologists	T097	UMLS:C0586884
27648073	70	94	Heavy Menstrual Bleeding	T038	UMLS:C0025323
27648073	107	131	Heavy menstrual bleeding	T038	UMLS:C0025323
27648073	133	136	HMB	T038	UMLS:C0025323
27648073	150	163	gynecological	T091	UMLS:C0018417
27648073	236	245	diagnosis	T033	UMLS:C0011900
27648073	250	260	treatments	T058	UMLS:C0087111
27648073	264	267	HMB	T038	UMLS:C0025323
27648073	271	285	Latin American	T098	UMLS:C1553378
27648073	287	289	LA	T098	UMLS:C1553378
27648073	291	322	obstetricians and gynecologists	T097	UMLS:C0586884
27648073	324	330	OBGYNs	T097	UMLS:C0586884
27648073	344	350	survey	T170	UMLS:C0038951
27648073	448	469	reproductive medicine	T091	UMLS:C0242668
27648073	473	479	OBGYNs	T097	UMLS:C0586884
27648073	488	490	LA	T098	UMLS:C1553378
27648073	491	500	countries	T082	UMLS:C0454664
27648073	534	563	multiple-choice questionnaire	T170	UMLS:C0034394
27648073	585	591	OBGYNs	T097	UMLS:C0586884
27648073	613	619	survey	T170	UMLS:C0038951
27648073	682	693	respondents	T098	UMLS:C0282122
27648073	705	721	accurate answers	T170	UMLS:C1706817
27648073	746	756	blood loss	T033	UMLS:C3163616
27648073	771	774	HMB	T038	UMLS:C0025323
27648073	808	813	women	T098	UMLS:C0043210
27648073	818	827	consulted	T058	UMLS:C0009818
27648073	835	838	HMB	T038	UMLS:C0025323
27648073	871	899	combined oral contraceptives	T103	UMLS:C0009906
27648073	901	905	COCs	T103	UMLS:C0009906
27648073	912	929	ethynyl estradiol	T103	UMLS:C0015011
27648073	949	958	treatment	T058	UMLS:C0087111
27648073	962	967	women	T098	UMLS:C0043210
27648073	973	976	HMB	T038	UMLS:C0025323
27648073	985	991	OBGYNs	T097	UMLS:C0586884
27648073	1020	1034	private sector	T098	UMLS:C0033176
27648073	1100	1103	HMB	T038	UMLS:C0025323
27648073	1111	1114	COC	T103	UMLS:C0009906
27648073	1130	1148	estradiol valerate	T103	UMLS:C0059623
27648073	1153	1162	dienogest	T103	UMLS:C0057916
27648073	1173	1187	levonorgestrel	T103	UMLS:C0023566
27648073	1200	1219	intrauterine system	T103	UMLS:C4293370
27648073	1250	1261	respondents	T098	UMLS:C0282122
27648073	1294	1297	HMB	T038	UMLS:C0025323
27648073	1301	1314	gynecological	T091	UMLS:C0018417
27648073	1339	1357	medical treatments	T058	UMLS:C0237078
27648073	1394	1399	women	T098	UMLS:C0043210
27648073	1404	1413	consulted	T058	UMLS:C0009818
27648073	1421	1424	HMB	T038	UMLS:C0025323